Pfizer - In April 2008, Celldex entered into an agreement with Pfizer under which Pfizer was granted an exclusive worldwide license to a therapeutic cancer vaccine candidate, CDX-110, in Phase 2 development for the treatment of glioblastoma multiforme (GBM). This agreement also gives Pfizer exclusive rights to the use of EGFRvIII vaccines in other potential indications. Under the licensing and development agreement, Pfizer made an upfront payment to Celldex of $40 million and a $10 million equity investment in Celldex. Pfizer will fund all development costs for these programs. Celldex is also eligible to receive milestone payments exceeding $390 million for the successful development and commercialization of CDX-110 and additional EGFRvIII vaccine products, as well as double-digit royalties on any product sales.

In December 2000, Celldex partnered with Pfizer Animal Health to apply Celldex's vaccine technologies to animal health and human food safety markets.

3M - In June 2008, Celldex announced multi-year clinical research collaborations with 3M to access their proprietary Immune Response Modifier Resiquimod™ and additional Toll-like receptor 7/8 agonists (TLR) for clinical study with Celldex’s proprietary APC Targeting Technology™ for use as vaccine adjuvants.

The Ludwig Institute for Cancer Research (LICR) – In October 2006, Celldex entered a multi-year clinical research collaboration focusing on a series of tumor-associated antigens (TAAs) for use in Celldex’s APC Targeting Technology™. These antigens, previously identified and characterized immunologically by LICR, will be added to Celldex’s development programs for a range of cancer types. Three of these antigens (NY-ESO-1, MAGE3, and MelanA) are being studied in non-small cell lung, ovarian, and bladder cancers, as well as melanoma, in an extended series of Phase 1/2 programs conducted by the LICR and its collaborators.

Medarex – Through our formation from within Medarex in October 2005, Celldex retains the exclusive right to use the Medarex ‘huMAb’ mice for the development of antibody-based immunotherapies (including our core APC Targeting Technology™), as well as the right to enter into ten (10) therapeutic antibody collaborations around novel targets.

The Rockefeller University – Celldex has licensed intellectual property from Rockefeller to target the DEC-205 family of mannose receptors in human dendritic cells, leveraging discoveries from the laboratories of Professor Ralph Steinman and Michel Nussenzweig. Professors Steinman and Nussenzweig also sit on our Scientific Advisory Board. DEC-205 is a key receptor for certain antigen processing pathways, and having access to this IP greatly enhances our ability to develop highly-targeted immunotherapies.

Celldex is also collaborating with Rockefeller to develop a novel vaccine against HIV, the virus known to cause AIDS. This project is supported through a $14 million grant from the Grand Challenges for Global Health program within the Bill & Melinda Gates Foundation. The project is using the same human antibodies to DEC-205 receptors to selectively initiate robust immune responses against specifically selected HIV antigens.

GlaxoSmithKline – In 1997, Celldex licensed a rotavirus strain to GlaxoSmithKline that was used in development of Rotarix®. Rotarix® has now been approved worldwide, most recently receiving marketing approval in the United States in 2008, triggering milestone payments to Celldex.

Vaccine Technologies, Inc. (VTI) – In January 2009, Celldex entered into an agreement with VTI under which VTI was granted a worldwide fee- and royalty-bearing exclusive license to develop and commercialize Celldex's CholeraGarde® and ETEC vaccine programs. The agreement includes upfront license fees, milestone payments and royalties on net sales of licensed products during the term of the agreement

Amgen – In March 2009, Celldex entered into an agreement with Amgen in which Celldex acquired exclusive rights to develop and commercialize two immune-stimulatory molecules known as FMS-like tyrosine kinase 3 ligand (Flt3L) and CD40 ligand (CD40L). These rights enhance Celldex’s Precision Targeted Immunotherapy Platform.